Beam Therapeutics Inc (NQ: BEAM )

27.50 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Beam Therapeutics Inc

< Previous 1 2 Next >
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces Transition of Chief Financial Officer
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024 
From Beam Therapeutics
Via GlobeNewswire
MarketBeat Week in Review – 3/4 – 3/8
The market rally continues as the February Jobs Report reignited the soft landing talk, but momentum could stall if next week's inflation readings come in hot 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Inc. (NASDAQ: BEAM) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Beam Therapeutics
Via GlobeNewswire
2 gene editing stocks to keep on your 2024 watchlist
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) 
Via MarketBeat
Exposures Product Safety
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
CRISPR Therapeutics sets sights on gene-editing cures for disease
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for 
Via MarketBeat
Exposures Product Safety
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026 
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
From Beam Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.